Learn About Cardiomyopathy Due to Anthracyclines
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Steven Lipshultz is a Pediatric Cardiologist in Buffalo, New York. Dr. Lipshultz and is rated as an Elite provider by MediFind in the treatment of Cardiomyopathy Due to Anthracyclines. His top areas of expertise are Cardiomyopathy Due to Anthracyclines, Cardiomyopathy, Dilated Cardiomyopathy (DCM), Heart Transplant, and Gastric Bypass.
Dana-Farber Cancer Institute, Inc.
Anju Nohria is a Cardiologist and an Advanced Heart Failure and Transplant Cardiologist in Boston, Massachusetts. Dr. Nohria and is rated as an Elite provider by MediFind in the treatment of Cardiomyopathy Due to Anthracyclines. Her top areas of expertise are Myocarditis, Cardiomyopathy, Heart Failure, Heart Transplant, and Cardiac Ablation. Dr. Nohria is currently accepting new patients.
Pawan Singal practices in Winnipeg, Canada. Singal and is rated as an Elite expert by MediFind in the treatment of Cardiomyopathy Due to Anthracyclines. His top areas of expertise are Doxorubicin-Induced Cardiomyopathy, Cardiomyopathy Due to Anthracyclines, Cardiomyopathy, and Heart Failure.
Summary: Acute myeloid leukemia (AML) is a clonal neoplastic disease of the hematopoietic tissue associated with a mutation in the precursor cell of hematopoiesis, which results in a differentiation block and uncontrolled proliferation of immature myeloid cells. Anthracycline antibiotics have been an integral part of the treatment of acute myeloid leukemia since the 1970s. However, the clinical usefulness ...
Summary: Patients treated for DLBCL are at high risk of developing AICD. This adverse event is characterized by irreversible damage to the heart muscle with a loss of cardiomyocytes and subsequent decline in cardiac pumping capacity. Thereby patients treated for this malignancy are at double the risk of developing symptomatic heart failure / cardiomyopathy when compared to the general population. This corr...